N-alpha-acetyltransferase 10

Gene and transcripts

The human NAA10 is located on chromosome Xq28 and contains 8 exons, 2 encoding three different isoforms derived from alternate splicing. Additionally, a processed NAA10 gene duplication NAA11 (ARD2) has been identified that is expressed in several human cell lines; however, later studies indicate that Naa11 is not expressed in the human cell lines HeLa and HEK293 or in cancerous tissues, and NAA11 transcripts were only detected in testicular and placental tissues. Naa11 has also been found in mouse, where it is mainly expressed in the testis. NAA11 is located on chromosome 4q21.21 in human and 5 E3 in mouse, and only contains two exons. Mice have another Naa10-like paralog, Naa12. Naa12 has NAT activity and genetically compensates for loss of Naa10, while being Naa10/Naa12 null is embryonic lethal in mic.

In mouse, NAA10 is located on chromosome X A7.3 and contains 9 exons. Two alternative splicing products of mouse Naa10, mNaa10235 and mNaa10225, were reported in NIH-3T3 and JB6 cells that may have different activities and function in different subcellular compartments.

Homologues for Naa10 have been identified in almost all kingdoms of life analyzed, including plants, fungi, amoebozoa, archaeabacteria and protozoa. In eubacteria, 3 Nα-acetyltransferases, RimI, RimJ and RimL, have been identified but according to their low sequence identity with the NATs, it is likely that the RIM proteins do not have a common ancestor and evolved independently.

Structure

Size-exclusion chromatography and circular dichroism indicated that human Naa10 consists of a compact globular region comprising two thirds of the protein and a flexible unstructured C-terminus. X-ray crystal structure of the 100 kD holo-NatA (Naa10/Naa15) complex from S. pombe showed that Naa10 adopts a typical GNAT fold containing a N-terminal α1–loop–α2 segment that features one large hydrophobic interface and exhibits interactions with its auxiliary subunit Naa15, a central acetyl CoA-binding region, and C-terminal segments that are similar to the corresponding regions in Naa50, another Nα-acetyltransferase. The X-ray crystal structure of archaeal T. volcanium Naa10 has also been reported, revealing multiple distinct modes of acetyl-Co binding involving the loops between β4 and α3, including the P-loop. Non-complexed (Naa15 unbound) Naa10 adopts a different fold: Leu22 and Tyr26 shift out of the active site of Naa10, and Glu24 (important for substrate binding and catalysis of NatA) is repositioned by ~5 Å, resulting in a conformation that allows for the acetylation of a different subset of substrates. An X-ray crystal structure of human Naa10 in complex with Naa15 and HYPK has been reported.

A functional nuclear localization signal in the C-terminus of hNaa10 between residues 78 and 83 (KRSHRR) has been described.

Function

Naa10, as part of the NatA complex, is bound to the ribosome and co-translationally acetylates proteins starting with small side chains such as Ser, Ala, Thr, Gly, Val and Cys, after the initiator methionine (iMet) has been cleaved by methionine aminopeptidases (MetAP). Furthermore, post-translational acetylation by non-ribosome-associated Naa10 might occur. About 40-50 % of all proteins are potential NatA substrates. Additionally, in a monomeric state, structural rearrangements of the substrate binding pocket Naa10 allow acetylation of N-termini with acidic side chains. Furthermore, Nε-acetyltransferase activity and N-terminal propionyltransferase activity have been reported.

Despite the fact that Nα-terminal acetylation of proteins has been known for many years, the functional consequences of this modification are not well understood. However, accumulating evidence have linked Naa10 to various signaling pathways, including Wnt/β-catenin, MAPK, JAK/STAT, and NF-κB, thereby regulating various cellular processes, including cell migration, cell cycle control, DNA damage control, caspase-dependent cell death, p53 dependent apoptosis, cell proliferation and autophagy as well as hypoxia, although there are some major discrepancies regarding hypoxia and even isoform specific effects of Naa10 functions have been reported in mouse.

Naa10 is essential in D. melanogaster, C. elegans and T. brucei. In S. cerevisiae, Naa10 function is not essential but yNAA10Δ cells display severe defects including de-repression of the silent mating type locus (HML), failure to enter Go phase, temperature sensitivity, and impaired growth. Naa10-knockout mice have very recently been reported to be viable, displaying a defect in bone development.

Disease

In 2001 A c.109TC (p.Ser37Pro) variant in NAA10 was identified in two unrelated families with Ogden Syndrome, a X-linked disorder involving a distinct combination of an aged appearance, craniofacial anomalies, hypotonia, global developmental delays, cryptorchidism, and cardiac arrhythmias. Patient fibroblasts displayed altered morphology, growth and migration characteristics and molecular studies indicate that this S37P mutation disrupts the NatA complex and decreases Naa10 enzymatic activity in vitro and in vivo.

Furthermore, two other mutations in Naa10 (R116W mutation in a boy and a V107F mutation in a girl) have been described in two unrelated families with sporadic cases of non-syndromic intellectual disabilities, postnatal growth failure, and skeletal anomalies. The girl was reported as having delayed closure of the fontanels, delayed bone age, broad great toes, mild pectus carinatum, pulmonary artery stenosis, atrial septal defect, prolonged QT interval. The boy was reported as having small hands/feet, high arched palate, and wide interdental spaces.

Additionally, a splice mutation in the intron 7 splice donor site (c.471+2T→A) of NAA10 was reported in a single family with Lenz microphthalmia syndrome (LMS), a very rare, genetically heterogeneous X-linked recessive disorder characterized by microphthalmia or anophthalmia, developmental delay, intellectual disability, skeletal abnormalities and malformations of teeth, fingers and toes. Patient fibroblasts displayed cell proliferation defects, dysregulation of genes involved in retinoic acid signaling pathway, such as STRA6, and deficiencies in retinol uptake.

Accumulating evidence suggests Naa10 function might regulate co-translational protein folding through the modulation of chaperone function, thereby affecting pathological formation of toxic amyloid aggregates in Alzheimer's disease or prion [PSI+] propagation in yeast.

Further information on NAA10 related syndromes can be found at www.naa10gene.com

Notes

References

References

1. (Jan 1995). "Isolation of new genes in distal Xq28: transcriptional map and identification of a human homologue of the ARD1 N-acetyl transferase of Saccharomyces cerevisiae". Human Molecular Genetics.
2. "Entrez Gene: ARD1A ARD1 homolog A, N-acetyltransferase (S. cerevisiae)".
3. (April 2012). "Protein N-terminal acetyltransferases: when the start matters". Trends in Biochemical Sciences.
4. (January 2007). "NCBI reference sequences (RefSeq): a curated non-redundant sequence database of genomes, transcripts and proteins". Nucleic Acids Research.
5. (25 April 2006). "Characterization of hARD2, a processed hARD1 gene duplicate, encoding a human protein N-alpha-acetyltransferase". BMC Biochemistry.
6. (November 2011). "Expression of human NAA11 (ARD1B) gene is tissue-specific and is regulated by DNA methylation". Epigenetics.
7. (August 2009). "Cloning, characterization, and expression analysis of the novel acetyltransferase retrogene Ard1b in the mouse". Biology of Reproduction.
8. (August 2021). "''Naa12'' compensates for ''Naa10'' in mice in the amino-terminal acetylation pathway". eLife.
9. (2 February 2007). "Differential regulation of splicing, localization and stability of mammalian ARD1235 and ARD1225 isoforms". Biochemical and Biophysical Research Communications.
10. (24 January 2003). "N-terminal acetyltransferases and sequence requirements for N-terminal acetylation of eukaryotic proteins". Journal of Molecular Biology.
11. (2013). "Identification and analysis of the acetylated status of poplar proteins reveals analogous N-terminal protein processing mechanisms with other eukaryotes". PLOS ONE.
12. (June 2012). "Comparative large scale characterization of plant versus mammal proteins reveals similar and idiosyncratic N-α-acetylation features". Molecular & Cellular Proteomics.
13. (December 1985). "The ARD1 gene of yeast functions in the switch between the mitotic cell cycle and alternative developmental pathways". Cell.
14. (June 2007). "An acetylase with relaxed specificity catalyses protein N-terminal acetylation in Sulfolobus solfataricus". Molecular Microbiology.
15. (1 November 2006). "Expression, crystallization and preliminary X-ray crystallographic analyses of two N-terminal acetyltransferase-related proteins from Thermoplasma acidophilum". Acta Crystallographica. Section F, Structural Biology and Crystallization Communications.
16. (October 2014). "Structure of Thermoplasma volcanium Ard1 belongs to N-acetyltransferase family member suggesting multiple ligand binding modes with acetyl coenzyme A and coenzyme A". Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics.
17. (December 2000). "Genetic manipulation indicates that ARD1 is an essential N(alpha)-acetyltransferase in Trypanosoma brucei". Molecular and Biochemical Parasitology.
18. (August 2008). "N-terminal processing of proteins exported by malaria parasites". Molecular and Biochemical Parasitology.
19. (1980). "Ribosomal protein modification in Escherichia coli. II. Studies of a mutant lacking the N-terminal acetylation of protein S18". Molecular & General Genetics.
20. (25 June 1979). "Ribosomal protein modification in Escherichia coli. I. A mutant lacking the N-terminal acetylation of protein S5 exhibits thermosensitivity". Journal of Molecular Biology.
21. (1981). "Ribosomal protein modification in Escherichia coli. III. Studies of mutants lacking an acetylase activity specific for protein L12". Molecular & General Genetics.
22. (October 2008). "Crystal structure of RimI from Salmonella typhimurium LT2, the GNAT responsible for N(alpha)-acetylation of ribosomal protein S18". Protein Science.
23. (15 August 2003). "Composition and function of the eukaryotic N-terminal acetyltransferase subunits". Biochemical and Biophysical Research Communications.
24. (August 2006). "Characterization of the native and fibrillar conformation of the human Nalpha-acetyltransferase ARD1". Protein Science.
25. (September 2013). "Molecular basis for N-terminal acetylation by the heterodimeric NatA complex". Nature Structural & Molecular Biology.
26. (10 May 2018). "Structure of Human NatA and Its Regulation by the Huntingtin Interacting Protein HYPK.". Structure.
27. (15 March 2005). "Identification and characterization of the human ARD1-NATH protein acetyltransferase complex". The Biochemical Journal.
28. (2014). "Nuclear translocation of hARD1 contributes to proper cell cycle progression". PLOS ONE.
29. (29 May 2009). "A novel human NatA Nalpha-terminal acetyltransferase complex: hNaa16p-hNaa10p (hNat2-hArd1)". BMC Biochemistry.
30. (July 2011). "NatF contributes to an evolutionary shift in protein N-terminal acetylation and is important for normal chromosome segregation". PLOS Genetics.
31. (May 2011). "Proteome-derived peptide libraries allow detailed analysis of the substrate specificities of N(alpha)-acetyltransferases and point to hNaa10p as the post-translational actin N(alpha)-acetyltransferase". Molecular & Cellular Proteomics.
32. (September 2004). "Berberine inhibits HIF-1alpha expression via enhanced proteolysis". Molecular Pharmacology.
33. (23 October 2014). "Arrest defective 1 regulates the oxidative stress response in human cells and mice by acetylating methionine sulfoxide reductase A". Cell Death & Disease.
34. (15 November 2006). "Human arrest defective 1 acetylates and activates beta-catenin, promoting lung cancer cell proliferation". Cancer Research.
35. (1 July 2008). "Hypoxia-inducible factor-1alpha obstructs a Wnt signaling pathway by inhibiting the hARD1-mediated activation of beta-catenin". Cancer Research.
36. (27 November 2002). "Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation". Cell.
37. (17 March 2010). "Roles of arrest-defective protein 1(225) and hypoxia-inducible factor 1alpha in tumor growth and metastasis". Journal of the National Cancer Institute.
38. (22 March 2006). "Metastasis-associated protein 1 enhances stability of hypoxia-inducible factor-1alpha protein by recruiting histone deacetylase 1". The EMBO Journal.
39. (January 2013). "Protein N-terminal acetyltransferases act as N-terminal propionyltransferases in vitro and in vivo". Molecular & Cellular Proteomics.
40. (1 June 2010). "Arrest defective 1 autoacetylation is a critical step in its ability to stimulate cancer cell proliferation". Cancer Research.
41. (August 2010). "hNaa10p contributes to tumorigenesis by facilitating DNMT1-mediated tumor suppressor gene silencing". The Journal of Clinical Investigation.
42. (October 2014). "Inhibition of STAT5a by Naa10p contributes to decreased breast cancer metastasis". Carcinogenesis.
43. (6 November 2009). "Phosphorylation of ARD1 by IKKbeta contributes to its destabilization and degradation". Biochemical and Biophysical Research Communications.
44. (1 June 2012). "ARD1 binding to RIP1 mediates doxorubicin-induced NF-κB activation". Biochemical and Biophysical Research Communications.
45. (June 2012). "N-α-acetyltransferase 10 protein inhibits apoptosis through RelA/p65-regulated MCL1 expression". Carcinogenesis.
46. (7 November 2014). "NAA10 controls osteoblast differentiation and bone formation as a feedback regulator of Runx2". Nature Communications.
47. (15 February 2011). "N-α-acetyltransferase 10 protein suppresses cancer cell metastasis by binding PIX proteins and inhibiting Cdc42/Rac1 activity". Cancer Cell.
48. (14 October 2009). "Arrest defective-1 controls tumor cell behavior by acetylating myosin light chain kinase". PLOS ONE.
49. (February 2007). "Interaction between beta-catenin and HIF-1 promotes cellular adaptation to hypoxia". Nature Cell Biology.
50. (15 December 2010). "Depletion of the human Nα-terminal acetyltransferase A induces p53-dependent apoptosis and p53-independent growth inhibition". International Journal of Cancer.
51. (20 October 2005). "Towards a proteome-scale map of the human protein-protein interaction network". Nature.
52. (19 November 2007). "A genome-wide RNAi screen reveals multiple regulators of caspase activation". The Journal of Cell Biology.
53. (19 August 2011). "Metabolic regulation of protein N-alpha-acetylation by Bcl-xL promotes cell survival". Cell.
54. (9 February 2010). "ARD1 stabilization of TSC2 suppresses tumorigenesis through the mTOR signaling pathway". Science Signaling.
55. (April 2005). "Down-regulation of the expression of the FIH-1 and ARD-1 genes at the transcriptional level by nickel and cobalt in the human lung adenocarcinoma A549 cell line". International Journal of Environmental Research and Public Health.
56. (19 July 2006). "Effect of connective tissue growth factor on hypoxia-inducible factor 1alpha degradation and tumor angiogenesis". Journal of the National Cancer Institute.
57. (21 November 2005). "Interaction between HIF-1 alpha (ODD) and hARD1 does not induce acetylation and destabilization of HIF-1 alpha". FEBS Letters.
58. (6 May 2005). "Analysis of ARD1 function in hypoxia response using retroviral RNA interference". The Journal of Biological Chemistry.
59. (2 September 2005). "Arrest-defective-1 protein, an acetyltransferase, does not alter stability of hypoxia-inducible factor (HIF)-1alpha and is not induced by hypoxia or HIF". The Journal of Biological Chemistry.
60. (12 May 2006). "Histone deacetylase inhibitors repress the transactivation potential of hypoxia-inducible factors independently of direct acetylation of HIF-alpha". The Journal of Biological Chemistry.
61. (3 April 2006). "Purified recombinant hARD1 does not catalyse acetylation of Lys532 of HIF-1alpha fragments in vitro". FEBS Letters.
62. (10 February 2006). "Characterization of ARD1 variants in mammalian cells". Biochemical and Biophysical Research Communications.
63. (November 2010). "Drosophila variable nurse cells encodes arrest defective 1 (ARD1), the catalytic subunit of the major N-terminal acetyltransferase complex". Developmental Dynamics.
64. (October 2014). "daf-31 encodes the catalytic subunit of N alpha-acetyltransferase that regulates Caenorhabditis elegans development, metabolism and adult lifespan". PLOS Genetics.
65. (October 1987). "The yeast ARD1 gene product is required for repression of cryptic mating-type information at the HML locus". Molecular and Cellular Biology.
66. (15 July 2011). "Using VAAST to identify an X-linked disorder resulting in lethality in male infants due to N-terminal acetyltransferase deficiency". American Journal of Human Genetics.
67. (8 December 2014). "Biochemical and cellular analysis of Ogden syndrome reveals downstream Nt-acetylation defects". Human Molecular Genetics.
68. (August 2014). "A Saccharomyces cerevisiae model reveals in vivo functional impairment of the Ogden syndrome N-terminal acetyltransferase NAA10 Ser37Pro mutant". Molecular & Cellular Proteomics.
69. (2012-11-10). "Range of genetic mutations associated with severe non-syndromic sporadic intellectual disability: an exome sequencing study". Lancet.
70. (6 August 2014). "De novo missense mutations in the NAA10 gene cause severe non-syndromic developmental delay in males and females". European Journal of Human Genetics.
71. (March 2014). "A splice donor mutation in NAA10 results in the dysregulation of the retinoic acid signalling pathway and causes Lenz microphthalmia syndrome". Journal of Medical Genetics.
72. (February 2005). "Interaction of N-terminal acetyltransferase with the cytoplasmic domain of beta-amyloid precursor protein and its effect on A beta secretion". Journal of Biochemistry.
73. (February 2009). "The NatA acetyltransferase couples Sup35 prion complexes to the [PSI+] phenotype". Molecular Biology of the Cell.
74. (15 July 2014). "Amyloid-associated activity contributes to the severity and toxicity of a prion phenotype". Nature Communications.
75. (15 July 2014). "Loss of amino-terminal acetylation suppresses a prion phenotype by modulating global protein folding". Nature Communications.